✦ LIBER ✦

Characterization of and costs associated to the profile of patients with type 2 diabetes treated with metformin who are added a second oral antidiabetic drug: A population study

✍ Scribed by Sicras-Mainar, Antoni; Font-Ramos, Beatriu; Roldán-Suárez, Cecilia; Navarro-Artieda, Ruth; Ibáñez-Nolla, Jordi

Book ID: 122319142
Publisher: Elsevier
Year: 2013
Weight: 774 KB
Volume: 60
Category: Article
ISSN: 2173-5093
DOI: 10.1016/j.endoen.2013.12.011

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapy conversion to insulin detemir am

Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: A modeling study of cost-effectiveness in the United States

✍ William J. Valentine; K. M. Erny-Albrecht; J. A. Ray; S. Roze; D. Cobden; A. J. 📂 Article 📅 2007 🏛 Springer Healthcare Communications 🌐 English ⚖ 225 KB

Self-monitoring of blood glucose (SMBG)

Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US

✍ Tunis, Sandra L.; Minshall, Michael E. 📂 Article 📅 2009 🏛 Informa plc 🌐 English ⚖ 488 KB

Comparative genotoxic and cytotoxic effe

Comparative genotoxic and cytotoxic effects of the oral antidiabetic drugs sitagliptin, rosiglitazone, and pioglitazone in patients with type-2 diabetes: A cross-sectional, observational pilot study

✍ Oz Gul, Ozen; Cinkilic, Nilufer; Gul, Cuma Bulent; Cander, Soner; Vatan, Ozgur; 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 503 KB

Efficacy and Safety Profile of Exenatide

Efficacy and Safety Profile of Exenatide Once Weekly Compared With Insulin Once Daily in Japanese Patients With Type 2 Diabetes Treated With Oral Antidiabetes Drug(s): Results From a 26-Week, Randomized, Open-Label, Parallel-Group, Multicenter, Noninferiority Study

✍ Inagaki, Nobuya; Atsumi, Yoshihito; Oura, Tomonori; Saito, Hitoshi; Imaoka, Take 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 962 KB

PDB50 Long-Term Clinical and Economic Be

PDB50 Long-Term Clinical and Economic Benefit Associated with Liraglutide Versus Sitagliptin Therapy When Added to Metformin in the Treatment of Type 2 Diabetes: a Core Diabetes Model Study

✍ W.C. Lee; Y. Samyshkin; J. Langer; J.L. Palmer 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 57 KB

Efficacy and safety of adding the dipept

Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study

✍ M. A. Nauck; G. C. Ellis; P. R. Fleck; C. A. Wilson; Q. Mekki; for the Aloglipti 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 218 KB